Down Syndrome Screening Testing: Methods, Markers, and Clinical Applications

Down syndrome screening testing is a prenatal laboratory service that evaluates the risk of fetal trisomy 21 through maternal serum biomarkers, ultrasound measurements, and cell-free DNA analysis. This article provides a comprehensive technical overview of sample types, screening analytes, analytical methodologies, and clinical applications to support healthcare providers and expectant parents in understanding laboratory-based prenatal risk assessment.

Technical Overview

Down syndrome, also known as trisomy 21, is the most common autosomal chromosomal abnormality in live births, caused by the presence of a full or partial extra copy of chromosome 21. Down syndrome screening testing refers to the laboratory and imaging procedures used to estimate the probability that a fetus is affected by trisomy 21, rather than to provide a definitive diagnosis. Screening results are typically expressed as a risk ratio, combining maternal age, gestational age, biochemical analyte concentrations, and, where applicable, fetal ultrasound measurements.

Modern screening strategies follow a layered approach: non-invasive serum and ultrasound screening in the first or second trimester, optional cell-free DNA (cfDNA) screening as a primary or contingent test, and confirmatory invasive diagnostic testing for screen-positive cases. Contemporary combined first-trimester screening achieves detection rates of approximately 85–90% at a 5% false-positive rate, while cfDNA-based screening exceeds 99% detection for trisomy 21 at false-positive rates below 1%. Laboratory operations should conform to quality management frameworks such as ISO 15189 for medical laboratories, with analytical performance validated against guidance from recognized clinical laboratory standards organizations.

Testing Samples

Maternal Serum

A venous blood sample of 2–5 mL collected from the pregnant woman is centrifuged to obtain serum for the measurement of biochemical markers such as PAPP-A, free beta-hCG, AFP, unconjugated estriol (uE3), and inhibin A. Serum samples are stable at 2–8°C for up to 48 hours; for longer transport times, frozen storage at -20°C or below is recommended. Accurate documentation of gestational age, maternal weight, age, ethnicity, smoking status, and diabetic status is essential, as these variables directly affect multiple-of-the-median (MoM) correction of analyte values.

Maternal Whole Blood for Cell-Free DNA Analysis

For non-invasive prenatal screening, 10–20 mL of maternal peripheral blood is collected into specialized cell-stabilizing tubes or EDTA tubes. Plasma is separated within a defined time window to preserve circulating cell-free fetal DNA, which typically constitutes 3–20% of total cfDNA after 10 weeks of gestation. The fetal fraction is a critical quality metric; results below approximately 4% fetal fraction are considered unreportable and require redraw.

Amniotic Fluid

For confirmatory diagnosis, 15–20 mL of amniotic fluid is obtained by amniocentesis, usually performed between 15 and 22 weeks of gestation under continuous ultrasound guidance. The sample contains viable fetal cells suitable for karyotyping, fluorescence in situ hybridization (FISH), quantitative fluorescent PCR (QF-PCR), and chromosomal microarray analysis.

Chorionic Villus Sample

Chorionic villus sampling (CVS), performed between 10 and 13 weeks of gestation via transabdominal or transcervical routes, yields placental trophoblast cells for rapid aneuploidy testing and full karyotype analysis. Because CVS samples placental tissue, confined placental mosaicism of approximately 1–2% incidence must be considered during interpretation.

Testing Items

Screening panels are organized by trimester and methodology. The principal testing items are listed below:

• First-trimester combined screening: pregnancy-associated plasma protein-A (PAPP-A), free beta-hCG or total hCG, and nuchal translucency (NT) measured by certified ultrasonography between 11 and 13⁺⁶ weeks.
• Second-trimester triple screen: alpha-fetoprotein (AFP), hCG, and unconjugated estriol (uE3).
• Second-trimester quadruple screen: AFP, hCG, uE3, and dimeric inhibin A, performed between 15 and 20 weeks of gestation.
• Integrated and sequential screening: combination of first-trimester and second-trimester serum markers with NT to maximize detection rates.
• Cell-free DNA screening (NIPT): genome-wide or targeted massively parallel sequencing of maternal plasma cfDNA for trisomy 21, 18, 13, and optional sex chromosome aneuploidies and selected microdeletion syndromes.
• Diagnostic confirmation items: G-banded karyotyping (resolution 320–550 bands), interphase FISH for chromosomes 21, 18, 13, X, and Y, QF-PCR for rapid aneuploidy detection, and chromosomal microarray analysis for copy number variants.
• Ancillary markers: nasal bone assessment, ductus venosus pulsatility index, and fetal facial angle as optional first-trimester ultrasonographic modifiers.

Testing Methods

Serum analytes are quantified using automated immunoassay platforms, including time-resolved fluorescence immunoassay (TRFIA) and chemiluminescent immunoassay (CLIA), calibrated against gestation-specific median values to generate MoM results. Risk calculation software integrates MoM values with maternal covariates using likelihood ratio algorithms to produce patient-specific risk figures.

Cell-free DNA screening employs either whole-genome massively parallel sequencing with bioinformatic z-score analysis of chromosome 21 representation, or targeted capture sequencing with single nucleotide polymorphism (SNP)-based analytical pipelines. Both approaches report trisomy 21 detection sensitivity above 99% and specificity above 99.9% in validated clinical studies.

Confirmatory diagnostic testing relies on classical cytogenetics and molecular cytogenetics. G-banded metaphase karyotyping remains the reference standard, requiring 7–14 days of cell culture. Rapid interphase FISH and QF-PCR deliver preliminary results within 24–48 hours by detecting copy number of chromosomes 21, 18, 13, X, and Y directly on uncultured cells. Chromosomal microarray analysis using array comparative genomic hybridization (aCGH) or SNP arrays offers enhanced resolution for submicroscopic pathogenic copy number variants. All methods undergo analytical validation, including sensitivity, specificity, precision, and reportable range studies, with participation in external quality assessment schemes accredited to ISO 17043.

Applications

Down syndrome screening testing is applied across diverse clinical scenarios:

• Routine prenatal risk assessment for all pregnant women as recommended by international obstetric guidelines.
• Targeted screening for pregnancies with elevated a priori risk, including advanced maternal age of 35 years or older at delivery.
• Follow-up evaluation of abnormal ultrasound findings, such as increased nuchal translucency, thickened nuchal fold, or structural anomalies.
• Screening in pregnancies conceived by assisted reproductive technology, where accurate risk stratification informs care planning.
• Contingent testing pathways in which cfDNA screening is offered to patients with intermediate serum screening risk results, reducing unnecessary invasive procedures.
• Diagnostic confirmation for screen-positive cases, enabling informed genetic counseling, pregnancy management decisions, and preparation for postnatal care.
• Public health screening programs and epidemiological surveillance of chromosomal abnormality incidence.

FAQ

What is the difference between screening and diagnostic testing?

Screening tests estimate the statistical probability that a fetus has trisomy 21 and cannot confirm or exclude the condition. Diagnostic tests such as amniocentesis with karyotyping, FISH, or microarray analyze fetal genetic material directly and provide definitive results exceeding 99% accuracy.

When should Down syndrome screening be performed?

First-trimester combined screening is performed between 11 and 13⁺⁶ weeks; second-trimester serum screening between 15 and 20 weeks; and cfDNA screening from 10 weeks of gestation onward. Diagnostic procedures are timed according to gestational age: CVS at 10–13 weeks and amniocentesis at 15–22 weeks.

What does a screen-positive result mean?

A positive screening result indicates that the risk exceeds the laboratory's defined cut-off, commonly 1 in 270 for trisomy 21 in second-trimester serum screening. Most screen-positive pregnancies are not affected; genetic counseling and confirmatory diagnostic testing are recommended.

How accurate is cell-free DNA screening?

CfDNA screening detects more than 99% of trisomy 21 cases with a false-positive rate below 0.1%. However, it remains a screening test, and all positive results must be confirmed by invasive diagnostic testing before irreversible clinical decisions are made.

How long does it take to receive results?

Serum screening results are typically issued within 3–5 working days. CfDNA screening results require approximately 5–10 working days. Rapid molecular diagnostic tests (FISH or QF-PCR) are reported within 24–48 hours, while full karyotype analysis requires 7–14 days due to cell culture time.

Are there risks associated with sample collection?

Serum and cfDNA screening involve a routine maternal blood draw with no risk to the fetus. Invasive diagnostic procedures carry a small procedural risk of miscarriage, generally quoted at approximately 0.1–0.3% when performed by experienced operators under continuous ultrasound guidance.